173 related articles for article (PubMed ID: 38025907)
1. Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.
Ferenczi K; Nagy ZF; Istenes I; Eid H; Bödör C; Timár B; Demeter J
Pathol Oncol Res; 2023; 29():1611378. PubMed ID: 38025907
[No Abstract] [Full Text] [Related]
2. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
[TBL] [Abstract][Full Text] [Related]
3. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
Handa S; Lee JO; Derkach A; Stone RM; Saven A; Altman JK; Grever MR; Rai KR; Shukla M; Vemuri S; Montoya S; Taylor J; Abdel-Wahab O; Tallman MS; Park JH
Blood; 2022 Dec; 140(25):2663-2671. PubMed ID: 35930750
[TBL] [Abstract][Full Text] [Related]
5. BRAF in the cross-hairs.
Geyer MB; Abdel-Wahab O; Tallman MS
Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
7. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S; Mutlu YG; Malkan ÜY; Mehtap Ö; Keklik Karadağ F; Korkmaz G; Elverdi T; Saydam G; Özet G; Ar MC; Melek E; Maral S; Kaynar L; Sevindik ÖG
Leuk Res; 2024 May; 140():107495. PubMed ID: 38599153
[TBL] [Abstract][Full Text] [Related]
8. Hairy cell leukemia: update and current therapeutic approach.
Salam L; Abdel-Wahab O
Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
[TBL] [Abstract][Full Text] [Related]
9. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Falini B; De Carolis L; Tiacci E
Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
[TBL] [Abstract][Full Text] [Related]
10. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.
Dietrich S; Pircher A; Endris V; Peyrade F; Wendtner CM; Follows GA; Hüllein J; Jethwa A; Ellert E; Walther T; Liu X; Dyer MJ; Elter T; Brummer T; Zeiser R; Hermann M; Herold M; Weichert W; Dearden C; Haferlach T; Seiffert M; Hallek M; von Kalle C; Ho AD; Gaehler A; Andrulis M; Steurer M; Zenz T
Blood; 2016 Jun; 127(23):2847-55. PubMed ID: 26941398
[TBL] [Abstract][Full Text] [Related]
11. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
[No Abstract] [Full Text] [Related]
12. New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell Leukemia.
Soong D; Taylor J
NEJM Evid; 2023 Oct; 2(10):EVIDe2300173. PubMed ID: 38320184
[TBL] [Abstract][Full Text] [Related]
13. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
14. New insights in the management of patients with hairy cell leukemia.
Cornet E; Damaj G; Troussard X
Curr Opin Oncol; 2015 Sep; 27(5):371-6. PubMed ID: 26154707
[TBL] [Abstract][Full Text] [Related]
15. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
Robak T; Robak P
Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
[TBL] [Abstract][Full Text] [Related]
16. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
17. Hairy cell leukemia-new genes, new targets.
Kreitman RJ
Curr Hematol Malig Rep; 2013 Sep; 8(3):184-95. PubMed ID: 23892906
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia: a 'hair-raising' update.
Topp ZZ; Saven A
Expert Rev Hematol; 2014 Oct; 7(5):659-69. PubMed ID: 25148599
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
Falini B; Martelli MP; Tiacci E
Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
[TBL] [Abstract][Full Text] [Related]
20. New treatment options in hairy cell leukemia with focus on BRAF inhibitors.
Falini B; Tiacci E
Hematol Oncol; 2019 Jun; 37 Suppl 1():30-37. PubMed ID: 31187521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
